Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHAVN Life Sciences Inc

HAVN Life Sciences Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-05T21:00:00Z
VOLUME
22105
Market Cap
0.33M

Momentum Score

…

HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.01
High
52 Week Price Range
0.01
Low
0.10
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public information on HAVN Life Sciences Inc (OTC: HAVLF) is limited and the company provides minimal regulatory filings and business disclosure. Long-term growth for small life-sciences issuers typically depends on successful product development or commercialization, regulatory progress, strategic partnerships and access to capital, factors that may support future revenue and market recognition and could attract investors seeking high-risk, high-reward opportunities.

Key risks include limited disclosure and transparency, very low trading liquidity on the OTC market, substantial financing and execution risk typical of microcap life-sciences companies, and regulatory or operational uncertainty.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.59M
Revenue Per Share
0.08
Gross Profit TTM
0.09M
Debt / Equity
0.12
ROE
-234.52%
Net Debt
-0.67M
ROCE
-283.40%
Diluted EPS TTM
-2.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly
Date 2022-04-30 2021-04-30 2020-04-30
Income before tax -22.44M -30.38M -0.04M
Net income -22.44M -30.38M -0.04M
Selling general administrative 8.46M 19.08M 0.04M
Selling and marketing expenses 0.21M 0.33M -
Gross profit 0.09M - -
Reconciled depreciation 0.58M 4.60M 0.00M
Ebit -9.78M -24.35M -0.49M
Ebitda -9.20M -19.74M -0.04M
Depreciation and amortization 0.58M 4.60M -
Operating income -9.81M -24.35M -0.04M
Other operating expenses 10.09M 24.35M 0.04M
Interest expense 0.06M 0.02M 0.00M
Interest income 0.03M 0.00M 0.00M
Net interest income -0.03M -0.02M 0.00M
Income tax expense 0.06M 0.02M -
Total revenue 0.28M 0.00M 0.00M
Total operating expenses 9.90M 24.35M 0.04M
Cost of revenue 0.19M - -
Total other income expense net -12.60M -6.02M -
Net income from continuing ops -22.44M -30.38M -0.04M
Net income applicable to common shares -22.44M -30.38M -0.49M
Breakdown 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly
Date 2022-04-30 2021-04-30 2020-04-30
Total assets 4.06M 14.24M 1.94M
Intangible assets 0.93M - -
Other current assets 0.22M - -
Total liab 0.92M 1.04M 0.04M
Total stockholder equity 3.14M 13.20M 1.90M
Other current liab 0.21M 0.58M -
Common stock 49.15M 37.00M 1.92M
Capital stock 49.15M 37.00M 1.92M
Retained earnings -52.86M -30.42M -0.04M
Other assets 0.02M 0.02M -
Cash 1.06M 9.40M 1.62M
Total current liabilities 0.61M 0.71M 0.04M
Net debt -0.67M -8.95M -1.62M
Short term debt 0.08M 0.13M -
Short long term debt total 0.39M 0.46M -
Other stockholder equity 6.85M 6.62M 0.02M
Property plant equipment 0.36M 0.68M -
Total current assets 2.75M 10.61M 1.94M
Net tangible assets 2.21M 10.27M 1.90M
Net receivables 0.32M 0.21M 0.25M
Inventory 1.15M 0.36M -
Accounts payable 0.32M 0.53M 0.04M
Non currrent assets other 0.02M 0.02M -
Non current assets total 1.31M 3.63M 0.00M
Capital lease obligations 0.39M 0.46M -
Breakdown 2022-04-30 2021-04-30 2020-04-30
Type yearly yearly yearly
Date 2022-04-30 2021-04-30 2020-04-30
Investments -2.03M -0.40M -0.25M
Change to liabilities -0.05M 0.51M 0.49M
Total cashflows from investing activities -2.03M -0.40M -3.00M
Net borrowings -0.13M -0.03M -0.03M
Total cash from financing activities 1.56M 18.60M 1.94M
Change to operating activities -0.37M -0.92M -0.90M
Net income -22.44M -30.38M -0.04M
Change in cash -8.35M 7.78M 1.62M
Begin period cash flow 9.40M 1.62M -0.00M
End period cash flow 1.06M 9.40M 1.62M
Total cash from operating activities -7.88M -10.42M -0.08M
Issuance of capital stock 2.00M 14.13M 1.92M
Depreciation 0.58M 4.60M 4.60M
Other cashflows from investing activities -0.76M -0.02M -3.00M
Change to account receivables -0.11M -0.21M -0.21M
Other cashflows from financing activities -0.31M 4.50M 0.02M
Change to netincome 14.53M 15.97M -0.01M
Capital expenditures 0.10M 0.03M 0.03M
Change in working capital -0.54M -0.62M -0.03M
Stock based compensation 1.79M 9.14M -
Other non cash items 12.74M 6.83M -0.00M
Free cash flow -7.98M -10.45M -0.08M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HAVLF
HAVN Life Sciences Inc		 -
-%		 0.00 - - 0.56 0.31 0.58 -0.02
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

HAVN Life Sciences Inc

HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.

22071 Fraserwood Way, Richmond, BC, Canada, V6W 1J5

604-687-7130

https://www.havnlife.com

Name Title Year Born
Mr. Tim Moore Interim CFO, CEO & Chairman 1958
Ms. Jenna Pozar Chief Operations Officer NA
Mr. Paul More Controller NA
Mr. Tim Moore Interim CFO, CEO & Chairman 1959

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…